Two CAR-T Cancer Immunotherapy Trials on Clinical Hold After Patient Death – P&T Community
Two CAR-T Cancer Immunotherapy Trials on Clinical Hold After Patient Death
The FDA has placed a clinical hold on two gene-edited allogeneic CAR T-cell (UCART) phase 1 studies being conducted by Cellectis after the report of a patient death. The studies are evaluating UCART123 immunotherapy in patients with acute myeloid ...
Patient Death Triggers FDA Hold For Cellectis's “Off the Shelf” CAR-T
Here's Why Cellectis SA Fell as Much as 31.6% Today
After Patient Death, FDA Places Clinical Hold on Cellectis CAR-T Candidate UCART123